The disposition kinetics of marbofloxacin at a single dose of 2 mg/kg bodyweight were determined in a crossover trial with five clinically healthy loggerhead sea turtles (Caretta caretta) after i.v. and i.m. administration. Marbofloxacin plasma concentrations were determined by high performance liquid chromatography (LOD/LOQ 0.05 μg/ml). Data were subjected to noncompartmental analysis. The integrated pharmacokinetic/pharmacodynamic variables showed that optimal area under the curve (AUC 0-24 h): minimal inhibitory concentration (MIC) (>125) and Cmax : MIC (> 8) ratios, as reported for concentration dependent bactericidal antimicrobials (e.g., fluoroquinolones), were achievable with both a once daily i.v. or i.m. dose for microorganisms with MIC ≤ 0.5 μg/ml, while a Cmax; MIC > 8 for MIC ≥ 1 μg/ml was achievable only after the i.v. administration. The absence of adverse reactions in the animals after i.v. or i.m. administration of marbofloxacin and the favorable pharmacokinetic/pharmacodynamic properties after a single dose of 2 mg/kg suggest the possibility of its safe and effective clinical use in loggerhead sea turtles.
Pharmacokinetics Of Marbofloxacin In Loggerhead Sea Turtles (Caretta Caretta) After Single Intravenous And Intramuscular Doses
LAI, OLIMPIA;CRESCENZO, Giuseppe;
2009-01-01
Abstract
The disposition kinetics of marbofloxacin at a single dose of 2 mg/kg bodyweight were determined in a crossover trial with five clinically healthy loggerhead sea turtles (Caretta caretta) after i.v. and i.m. administration. Marbofloxacin plasma concentrations were determined by high performance liquid chromatography (LOD/LOQ 0.05 μg/ml). Data were subjected to noncompartmental analysis. The integrated pharmacokinetic/pharmacodynamic variables showed that optimal area under the curve (AUC 0-24 h): minimal inhibitory concentration (MIC) (>125) and Cmax : MIC (> 8) ratios, as reported for concentration dependent bactericidal antimicrobials (e.g., fluoroquinolones), were achievable with both a once daily i.v. or i.m. dose for microorganisms with MIC ≤ 0.5 μg/ml, while a Cmax; MIC > 8 for MIC ≥ 1 μg/ml was achievable only after the i.v. administration. The absence of adverse reactions in the animals after i.v. or i.m. administration of marbofloxacin and the favorable pharmacokinetic/pharmacodynamic properties after a single dose of 2 mg/kg suggest the possibility of its safe and effective clinical use in loggerhead sea turtles.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
